Hugh McDevitt (1), Goonaseelan Pillai (1), Kai Wu (1), Ramprasad Ramakrishna (1), Gerard JP Flesch (1), Georges Ette (1), Sreeni Devidas (2), Rajasekhar Thatavarti (2), Vincent Buchheit (1). Infrastructure development for building, maintaining and modeling indication- specific summary-level literature databases to support model based drug development.
|
Dalia A. Vásquez-Bahena (1), Uzziel E. Salazar-Morales (1), Mario I. Ortiz (2), Gilberto Castañeda-Hernández (1) and Iñaki F. Trocóniz (3). Population Pharmacokinetic-pharmacodynamic modeling of the Analgesic Effects of Lumiracoxib, a selective inhibitor of the enzyme COX2 in the Rat
|
Leonid Gibiansky (1), Ekaterina Gibiansky (2) Pharmacodynamic Modeling of Biologics with Target-Mediated Drug Disposition: TMDD Approximations, Relation to Indirect-Response Models, and Application to Population PK-PD Analyses
|
Alienor Berges, Bart Laurijssens, Chao Chen An Efficiency Comparison between Concentration-Response Analysis and Dose-Response Analysis through Simulation
|
D. Renard, K. Wu, R. Wada, G. Flesch Using desirability indices for decision making in drug development
|
Jeroen Elassaiss-Schaap and Siem Heisterkamp Variability as constant coefficient of variation: Can we right two decades in error?
|
P. L. S. Chan (1), P. Jacqmin (2), M. Lavielle (3), L. McFadyen (1), B. Weatherley (1) Population Pharmacokinetic-Pharmacodynamic-Viral Dynamics Modelling of Maraviroc Monotherapy Data Using MONOLIX
|
Paul G. Baverel, Radojka M. Savic, Mats O. Karlsson Two PsN Bootstrapping Routines for Obtaining Uncertainty Measurement around the Nonparametric Distribution Obtained in NONMEM VI
|
S. Goutelle (1,2), L. Bourguignon (1,2), N. Bleyzac (1,3), P. Maire (1,2), R.W. Jelliffe (4) Performing Monte Carlo Simulation Based on Nonparametric Pharmacokinetic Parameter Distributions: Evaluation of Various Methods Applied to a Paediatric Population Study on Busulfan
|
C. Castelain (1), A. Dalis (1), X. Deflorenne (1), M. Destrée (1), B. Lacroix (2), L. Sargentini-Maier (2) Implementation of a NONMEM cluster and add-ons within UCB
|
N. Snelder (2), C. Diack (2), N. Benson (1), B. Ploeger (2), P. van der Graaf (1) A proposal for implementation of the Markov property into a continuous time transition state model in NONMEM
|
James Yates, Rebecca Watson and Jason Cheung Validation of in vivo Mouse PK Assay by Mixed Effects Modelling: Estimation of between-study variability.
|
I. Ince(1,2), S.N. de Wildt(1), M.Y.M. Peeters(3), N.J. Vet(1), D. Tibboel(1), M. Danhof(2), C.A. Knibbe(1,2,3) Population PK modeling of Midazolam in Children; The effect of age versus other covariates
|
M.A. Boroujerdi (1), C. van Kesteren (1), A. Facius (2), M. Danhof (1), O.E. Della Pasqua (1,3) A turnover longitudinal model for the analysis of FEV1 changes in COPD
|
Navarro-Fontestad C. (1), Fernandez-Teruel C. (2), Gonzalez-Alvarez . (3), Garcia-Arieta A. (4), Bermejo M. (3), Casabo VG. (1). Bioequivalence Trials Simulation to Select the Best Analyte for Drugs with Presystemic Intestinal and Hepatic Metabolism.
|
S. Saleh(1), H. Staß(1), G. Ahr(1), R. Burghaus(1) Matching PBPK and NONMEM pharmacokinetics descriptions to understand and extrapolate - case study ciprofloxacin
|
Ashley Strougo(1,2); Walter Krauwinkel(1); Meindert Danhof(2); Jan Freijer(1) Mechanism-based pharmacokinetic modelling to describe the effect of protein binding on the pharmacokinetics of solifenacin
|
Emilie HÉNIN, Martin BERGSTRAND, Mats O. KARLSSON Tablet position in gastrointestinal tract derived from drug release measurements and plasma concentrations
|
Varun Goel (1), Timothy E Hanson (2), Brian Corrigan (3), Raymond Miller (3), Richard C Brundage (1) A Bayesian Multivariate Model for Repeated Measures of Correlated Data
|
H. Kramer1, A. Zandvliet1, R. Berg2, HJ Streefkerk4, P. Grobara3, P Peeters2, T Kerbusch1 Phase II dose selection for a hypothetical novel Direct Thrombin Inhibitor (DTI): an integrated approach using experimental and literature data.
|